{
      "Rank": 129,
      "Acronym": [
            "START"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [
            "No"
      ],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [
            "No"
      ],
      "ArmGroupDescription": [
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A was administered intravenously over approximately 60-80 minutes."
      ],
      "ArmGroupInterventionName": [
            "Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells",
            "Biological: Plasma-Lyte A"
      ],
      "ArmGroupLabel": [
            "Human Mesenchymal Stromal Cells (hMSCs)",
            "Plasma-Lyte A (placebo)"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [
            "<=18 years",
            "Between 18 and 65 years",
            ">=65 years",
            "Female",
            "Male",
            "Hispanic or Latino",
            "Not Hispanic or Latino",
            "Unknown or Not Reported",
            "American Indian or Alaska Native",
            "Asian",
            "Native Hawaiian or Other Pacific Islander",
            "Black or African American",
            "White",
            "More than one race",
            "Unknown or Not Reported",
            "Sepsis with pneumonia",
            "Sepsis without pneumonia",
            "Pneumonia without sepsis",
            "Aspiration only",
            "Other",
            "Volume control",
            "Pressure-regulated volume control",
            "Other"
      ],
      "BaselineClassDenomCountGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002"
      ],
      "NCTId": [
            "NCT02097641"
      ],
      "BaselineClassDenomCountValue": [
            "40",
            "20",
            "60",
            "40",
            "20",
            "60",
            "40",
            "20",
            "60",
            "40",
            "20",
            "60",
            "40",
            "20",
            "60",
            "40",
            "20",
            "60",
            "40",
            "20",
            "60",
            "40",
            "20",
            "60",
            "40",
            "20",
            "60",
            "40",
            "19",
            "59",
            "40",
            "19",
            "59",
            "40",
            "20",
            "60",
            "40",
            "20",
            "60",
            "39",
            "20",
            "59",
            "37",
            "19",
            "56",
            "30",
            "15",
            "45",
            "40",
            "20",
            "60",
            "30",
            "15",
            "45",
            "40",
            "20",
            "60",
            "37",
            "19",
            "56",
            "40",
            "20",
            "60",
            "40",
            "20",
            "60"
      ],
      "BaselineClassDenomUnits": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "BaselineClassTitle": [
            "United States"
      ],
      "BaselineDenomCountGroupId": [
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineDenomCountValue": [
            "40",
            "20",
            "60"
      ],
      "BaselineDenomUnits": [
            "Participants"
      ],
      "BaselineGroupDescription": [
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "Total of all reporting groups"
      ],
      "BaselineGroupId": [
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineGroupTitle": [
            "Human Mesenchymal Stem Cells (hMSCs)",
            "Plasma-Lyte A (Placebo)",
            "Total"
      ],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [
            "SOFA score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems which are added up. Each score ranges from 0 to 4. SOFA score ranges from 0 (best) to 24 (worst).",
            "The range of APACHE III is from 0 to 299. The higher score, the worse clinical outcome.",
            "Oxygenation index calculated as: FiO2 (%) x Mean Airway Pressure / PaO2",
            "LIS is a composite 4-point scoring system including the PaO2/FiO2, PEEP, lung compliance, and the extent of infiltrates on the chest X-ray. Each of the four components is categorized from 0 to 4, where a higher number is worse. The total Lung Injury Score is obtained by dividing the aggregate sum by the number of components used."
      ],
      "BaselineMeasureDispersionType": [
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation"
      ],
      "BaselineMeasureParamType": [
            "Count of Participants",
            "Mean",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Number",
            "Count of Participants",
            "Mean",
            "Count of Participants",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Count of Participants"
      ],
      "BaselineMeasurePopulationDescription": [
            "Data not recorded in one patient treated with Plasma-Lyte A (placebo).",
            "Data not recorded in one patient treated with Plasma-Lyte (placebo).",
            "Data not recorded in one patient treated with hMSCs.",
            "Data not recorded in three patients treated with hMSCs and one patient treated with Plasma-Lyte A (placebo).",
            "15 patients did not have baseline plateau pressure recorded.",
            "Data not recorded in 10 patients treated with hMSCs and in 5 patients treated with Plasma-Lyte (placebo).",
            "Data not recorded in 3 patients treated with hMSCs and 1 patient treated with Plasma-Lyte (placebo)."
      ],
      "BaselineMeasureTitle": [
            "Age, Categorical",
            "Age, Continuous",
            "Sex: Female, Male",
            "Ethnicity (NIH/OMB)",
            "Race (NIH/OMB)",
            "Region of Enrollment",
            "Cause of Acute Respiratory Distress Syndrome (ARDS)",
            "Arterial pressure",
            "Taking vasopressors at the time of infusion",
            "Sequential Organ Failure Assessment (SOFA)",
            "Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) III score",
            "Minute ventilation",
            "Respiratory rate",
            "Tidal volume",
            "Mean airway pressure",
            "Plateau airway pressure",
            "Positive end-expiratory pressure (PEEP)",
            "Driving pressure",
            "PaO2/FiO2",
            "Oxygenation index",
            "Lung injury score (LIS)",
            "Ventilation mode"
      ],
      "BaselineMeasureUnitOfMeasure": [
            "Participants",
            "years",
            "Participants",
            "Participants",
            "Participants",
            "participants",
            "Participants",
            "mm Hg",
            "Participants",
            "units on a scale",
            "units on a scale",
            "L/min",
            "breaths/min",
            "mL/kg predicted body weight",
            "cm H2O",
            "cm H2O",
            "cm H2O",
            "cm H2O",
            "kPa",
            "kPa",
            "units on a scale",
            "Participants"
      ],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [
            "17",
            "20",
            "18",
            "10",
            "9",
            "10",
            "3.3",
            "2.7",
            "3.2",
            "31",
            "33",
            "32",
            "3.2",
            "2.4",
            "3.0",
            "6.6",
            "6.3",
            "6.6",
            "0.9",
            "0.7",
            "0.9",
            "4.9",
            "3.6",
            "4.6",
            "5.7",
            "5.1",
            "5.6",
            "3.7",
            "2.6",
            "3.4",
            "4.1",
            "4.3",
            "4.2",
            "4.3",
            "5.2",
            "4.6",
            "45.9",
            "41.2",
            "44.4",
            "0.4",
            "0.5",
            "0.4"
      ],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [
            "0",
            "0",
            "0",
            "30",
            "12",
            "42",
            "10",
            "8",
            "18",
            "55",
            "55",
            "55",
            "23",
            "10",
            "33",
            "17",
            "10",
            "27",
            "4",
            "2",
            "6",
            "31",
            "16",
            "47",
            "5",
            "2",
            "7",
            "0",
            "0",
            "0",
            "2",
            "2",
            "4",
            "3",
            "0",
            "3",
            "4",
            "1",
            "5",
            "27",
            "13",
            "40",
            "0",
            "0",
            "0",
            "4",
            "4",
            "8",
            "40",
            "20",
            "60",
            "19",
            "12",
            "31",
            "5",
            "2",
            "7",
            "11",
            "5",
            "16",
            "4",
            "1",
            "5",
            "1",
            "0",
            "1",
            "75",
            "76",
            "75",
            "24",
            "9",
            "33",
            "8.1",
            "6.9",
            "7.7",
            "104",
            "89",
            "99",
            "11.1",
            "9.6",
            "10.6",
            "27.8",
            "24.5",
            "26.7",
            "6.3",
            "6.1",
            "6.2",
            "17.8",
            "16.4",
            "17.4",
            "26.4",
            "23.7",
            "25.5",
            "12.4",
            "10.8",
            "11.8",
            "14.0",
            "12.5",
            "13.5",
            "18.1",
            "19.1",
            "18.4",
            "108.1",
            "95.7",
            "103.9",
            "3.1",
            "3.0",
            "3.1",
            "37",
            "17",
            "54",
            "1",
            "2",
            "3",
            "2",
            "1",
            "3"
      ],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS)."
      ],
      "BriefTitle": [
            "Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "NIH",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER"
      ],
      "CollaboratorName": [
            "National Heart, Lung, and Blood Institute (NHLBI)",
            "Massachusetts General Hospital",
            "Stanford University",
            "University of Pittsburgh",
            "University of Minnesota",
            "Ohio State University"
      ],
      "CompletionDate": [
            "February 9, 2018"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Respiratory Distress Syndrome, Adult"
      ],
      "ConditionAncestorId": [
            "D000004194",
            "D000010335",
            "D000008171",
            "D000012140",
            "D000012120",
            "D000007235",
            "D000007232",
            "D000055370"
      ],
      "ConditionAncestorTerm": [
            "Disease",
            "Pathologic Processes",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Lung Injury"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC08",
            "BC16",
            "BC26",
            "BXS",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Respiratory Tract (Lung and Bronchial) Diseases",
            "Diseases and Abnormalities at or Before Birth",
            "Wounds and Injuries",
            "Urinary Tract, Sexual Organs, and Pregnancy Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Syndrome",
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome"
      ],
      "ConditionBrowseLeafId": [
            "M15507",
            "M14117",
            "M14116",
            "M27297",
            "M27296",
            "M10320",
            "M14129",
            "M14109",
            "M25022",
            "M9431",
            "M9428",
            "T4927",
            "T192",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "Syndrome",
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury",
            "Lung Injury",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Premature Birth",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Respiratory Distress Syndrome, Infant",
            "Acute Respiratory Distress Syndrome",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "low"
      ],
      "ConditionMeshId": [
            "D000012128",
            "D000012127",
            "D000055371",
            "D000013577"
      ],
      "ConditionMeshTerm": [
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury",
            "Syndrome"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Triple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator"
      ],
      "DetailedDescription": [
            "We carried out a randomized, double-blind placebo-controlled trial of allogeneic bone marrow derived human mesenchymal stromal cells for treatment of moderate to severe ARDS in 60 patients, 40 MSC and 20 placebo, in a 2:1 randomization. This trial is the extension of the Phase 1 pilot trial (NCT01775774). Patients were followed daily for adverse events through day 28, death or hospital discharge, whichever occurs first. Vital status was collected at 6 and 12 months after study enrollment."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatients will be eligible for inclusion if they meet all of the below criteria. Criteria 1-3 must all be present within a 24-hour time period and at the time of enrollment:\n\nAcute onset (defined below) of:\n\nA need for positive pressure ventilation by an endotracheal or tracheal tube with a PaO2/FiO2 ratio < 200 with at least 8 cm H2O positive end-expiratory airway pressure (PEEP)\nBilateral infiltrates consistent with pulmonary edema on frontal chest radiograph\nNo clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.\n\nExclusion Criteria:\n\nAge less than 18 years\nGreater than 96 hours since first meeting ARDS criteria per the Berlin definition of ARDS\nPregnant or breast-feeding\nPrisoner\nPresence of any active malignancy (other than non-melanoma skin cancer) that required treatment within the last 2 years\nAny other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%\nModerate to severe liver failure (Childs-Pugh Score > 12)\nSevere chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen\nPatient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)\nMajor trauma in the prior 5 days\nLung transplant patient\nNo consent/inability to obtain consent\nMoribund patient not expected to survive 24 hours\nWorld Health Organization (WHO) Class III or IV pulmonary hypertension\nDocumented deep venous thrombosis or pulmonary embolism within past 3 months\nNo arterial line/no intent to place an arterial line\nNo intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol\nCurrently receiving extracorporeal life support (ECLS) or high-frequency oscillatory ventilation (HFOV)"
      ],
      "EnrollmentCount": [
            "60"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [
            "15",
            "5"
      ],
      "EventGroupDeathsNumAtRisk": [
            "40",
            "20"
      ],
      "EventGroupDescription": [
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes."
      ],
      "EventGroupId": [
            "EG000",
            "EG001"
      ],
      "EventGroupOtherNumAffected": [
            "2",
            "2"
      ],
      "EventGroupOtherNumAtRisk": [
            "40",
            "20"
      ],
      "EventGroupSeriousNumAffected": [
            "17",
            "11"
      ],
      "EventGroupSeriousNumAtRisk": [
            "40",
            "20"
      ],
      "EventGroupTitle": [
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A"
      ],
      "EventsDescription": [
            "All-cause mortality by day 60 after study product infusion\nSerious adverse events, expected and unexpected, also included any deaths through study day 28 (none of them were related to study product or study procedures per DSMB review)\nPlease see our Lancet Resp Medicine 2018 publication (citation included) for further details including adjusted analyses of baseline differences between the MSC and placebo treated groups"
      ],
      "EventsFrequencyThreshold": [
            "0"
      ],
      "EventsTimeFrame": [
            "60 days"
      ],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001"
      ],
      "FlowAchievementNumSubjects": [
            "40",
            "20",
            "40",
            "20",
            "0",
            "0"
      ],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes."
      ],
      "FlowGroupId": [
            "FG000",
            "FG001"
      ],
      "FlowGroupTitle": [
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A"
      ],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED"
      ],
      "FlowPeriodTitle": [
            "Overall Study"
      ],
      "FlowPreAssignmentDetails": [
            "Three patients who were randomly assigned to receive human mesenchymal stem cells, were excluded: 2 did not meet baseline stability criteria; 1 patient's PaO2:FiO2 > 200 mmHg."
      ],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [
            "From March 24, 2014, to Feb 9, 2017, 1038 patients were screened for eligibility, of whom 975 were excluded, and 63 were randomly assigned to a treatment group. Three patients were not eligible for treatment after randomization and, therefore, 40 patients received human mesenchymal stem cells and 20 patients received placebo."
      ],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000009883",
            "D000019999"
      ],
      "InterventionAncestorTerm": [
            "Ophthalmic Solutions",
            "Pharmaceutical Solutions"
      ],
      "InterventionArmGroupLabel": [
            "Human Mesenchymal Stromal Cells (hMSCs)",
            "Plasma-Lyte A (placebo)"
      ],
      "InterventionBrowseBranchAbbrev": [
            "PhSol",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Pharmaceutical Solutions",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "Chronic Lung Disease"
      ],
      "InterventionBrowseLeafId": [
            "M85407",
            "M21013",
            "M11966"
      ],
      "InterventionBrowseLeafName": [
            "Plasma-lyte 148",
            "Pharmaceutical Solutions",
            "Ophthalmic Solutions"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.",
            "Plasma-Lyte A placebo was administered intravenously over approximately 60-80 minutes."
      ],
      "InterventionMeshId": [
            "C000012499"
      ],
      "InterventionMeshTerm": [
            "Plasma-lyte 148"
      ],
      "InterventionName": [
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells",
            "Plasma-Lyte A"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Biological"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells",
            "Acute Respiratory Distress Syndrome"
      ],
      "LargeDocDate": [
            "February 17, 2015"
      ],
      "LargeDocFilename": [
            "Prot_SAP_000.pdf"
      ],
      "LargeDocHasICF": [
            "No"
      ],
      "LargeDocHasProtocol": [
            "Yes"
      ],
      "LargeDocHasSAP": [
            "Yes"
      ],
      "LargeDocLabel": [
            "Study Protocol and Statistical Analysis Plan"
      ],
      "LargeDocTypeAbbrev": [
            "Prot_SAP"
      ],
      "LargeDocUploadDate": [
            "01/07/2019 14:42"
      ],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "April 10, 2019"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "March 18, 2019"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Michael A. Matthay"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "San Francisco",
            "Stanford",
            "Boston",
            "Saint Paul",
            "Columbus",
            "Pittsburgh"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States"
      ],
      "LocationFacility": [
            "University of California San Francisco",
            "Stanford University",
            "Massachusetts General Hospital",
            "University of Minnesota Medical Center",
            "Ohio State University",
            "University of Pittsburgh"
      ],
      "LocationState": [
            "California",
            "California",
            "Massachusetts",
            "Minnesota",
            "Ohio",
            "Pennsylvania"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "94143",
            "94305",
            "02114",
            "55108",
            "43210",
            "15213"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS)"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "University of California, San Francisco"
      ],
      "OrgStudyId": [
            "UCSF-hMSC-ARDS-P2"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment"
      ],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [
            "Hepatobiliary disorders",
            "Renal and urinary disorders",
            "Vascular disorders",
            "Blood and lymphatic system disorders"
      ],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "OtherEventStatsNumAffected": [
            "1",
            "0",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1"
      ],
      "OtherEventStatsNumAtRisk": [
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20"
      ],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [
            "Hepatitis",
            "Fecal and urinary incontinence",
            "Deep venous thrombosis",
            "Acute anemia"
      ],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeDenomCountValue": [
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "30",
            "18",
            "31",
            "18",
            "24",
            "14",
            "37",
            "19",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "39",
            "19",
            "38",
            "18",
            "39",
            "19",
            "38",
            "18",
            "39",
            "19",
            "38",
            "18",
            "39",
            "19",
            "38",
            "18"
      ],
      "OutcomeDenomUnits": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeGroupDescription": [
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells administered intravenously over approximately 60-80 minutes.\n\nAllogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.",
            "A single dose of Plasma-Lyte A will be administered intravenously over approximately 60-80 minutes.\n\nPlasma-Lyte A: Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes."
      ],
      "OutcomeGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeGroupTitle": [
            "Human Mesenchymal Stem Cells (hMSCs)",
            "Plasma-Lyte A (Placebo)",
            "Human Mesenchymal Stem Cells (hMSCs)",
            "Plasma-Lyte A (Placebo)",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A",
            "Human Mesenchymal Stem Cells",
            "Plasma-Lyte A"
      ],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [
            "Within 6 h of study product infusion:\n\nIncrease in vasopressor dose to the following values or higher:\nNorepinephrine 10 \u03bcg/min\nPhenylephrine 100 \u03bcg/min\nDopamine 10 \u03bcg/kg per min\nEpinephrine 0.1 \u03bcg/kg per min or addition of a third vasopressor\nNew ventricular tachycardia, ventricular fibrillation or asystole\nNew cardiac arrhythmia requiring cardioversion\nHypoxaemia requiring an increase in FiO2 of 0\u00b72 or more and an increase in PEEP of 5\u00b70 or more to maintain SpO2 in the target range of 88-95%\nClinical scenario consistent with transfusion incompatibility or transfusion-related infection (eg, urticaria, new bronchospasm)",
            "Within 24 h of study product infusion\n\n\u2022 Any cardiac arrest or death",
            "Safety endpoint: Any unexpected severe adverse events in two groups",
            "Efficacy endpoint: PaO2:FiO2 change from baseline to day 3",
            "Murray score for acute lung injury. The range is 0 to 4. The higher score, the worst outcome.",
            "Oxygenation index with the following validated measure of respiratory function: FiO2 (%) x mean airway pressure / PaO2",
            "Sequential organ failure assessment score (SOFA). The SOFA score ranges from 0 to 24. The higher, the worse.",
            "Efficacy endpoint: all-cause mortality at day 28",
            "Efficacy endpoint: all-cause mortality at day 60",
            "Efficacy endpoint: Number of ventilator-free days to day 28.",
            "Efficacy endpoint: Non-pulmonary organ-failure-free days to day 28",
            "Biological markers of endothelial injury: angiopoietin 2",
            "Biological markers of endothelial injury: angiopoietin 2",
            "Biological markers of inflammation: interleukin 6",
            "Biological markers of inflammation: interleukin 6",
            "Biological markers of inflammation: interleukin 8",
            "Biological markers of inflammation: interleukin 8",
            "Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)",
            "Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)"
      ],
      "OutcomeMeasureDispersionType": [
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range"
      ],
      "OutcomeMeasureParamType": [
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Median",
            "Median",
            "Median",
            "Median",
            "Count of Participants",
            "Count of Participants",
            "Median",
            "Median",
            "Median",
            "Median",
            "Median",
            "Median",
            "Median",
            "Median",
            "Median",
            "Median"
      ],
      "OutcomeMeasurePopulationDescription": [
            "The values of PaO2:FiO2 were not available in 10 patients treated with hMSCs and in 2 patients treated with placebo.",
            "The values were missing in 9 hMSC patients and 2 placebo patients.",
            "The values were missing in 16 patients treated by MSC and 6 patients treated by placebo",
            "The values were missing in 3 MSC patients and 1 placebo patient.",
            "The biomarker values were missing in one patient treated with hMSC and one patient treated with placebo.",
            "The values were not available in two patients treated with hMSC and two patients treated with placebo.",
            "The values were not available in one patient treated with hMSC and one patient treated with placebo.",
            "The values were not available in two patients treated with hMSC and two patients treated with placebo.",
            "The values were not available in one patient treated with hMSC and one patient treated with placebo.",
            "The values were not available in two patients treated with hMSC and two patients treated with placebo.",
            "The values were not available in one patient treated with hMSC and one patient treated with placebo.",
            "The values were not available in two patients treated with hMSC and two patients treated with placebo."
      ],
      "OutcomeMeasureReportingStatus": [
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted"
      ],
      "OutcomeMeasureTimeFrame": [
            "6 hours",
            "24 hours",
            "12 months",
            "baseline and day 3",
            "baseline and day 3",
            "baseline and day 2",
            "baseline and day 3",
            "28 days",
            "60 days",
            "28 days",
            "28 days",
            "baseline and 6 hours",
            "baseline and 24 hours",
            "baseline and 6 hours",
            "baseline and 24 hours",
            "baseline and 6 hours",
            "baseline and 24 hours",
            "baseline and 6 hours",
            "baseline and 24 hours"
      ],
      "OutcomeMeasureTitle": [
            "Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion",
            "Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion",
            "Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)",
            "PaO2:FiO2 Change From Baseline to Day 3",
            "Lung Injury Score From Baseline to Day 3",
            "Oxygenation Index Change From Baseline to Day 2",
            "SOFA Score Change From Baseline to Day 3",
            "Number of Patients Death to Day 28",
            "Mortality to Day 60",
            "Number of Ventilator-free Days to Day 28",
            "Non-pulmonary Organ-failure-free Days to Day 28",
            "Angiopoietin 2 Change From Baseline to 6 h",
            "Angiopoietin 2 Change From Baseline to 24 h",
            "Interleukin 6 Change From Baseline to 6 h",
            "Interleukin 6 Change From Baseline to 24 h",
            "Interleukin 8 Change From Baseline to 6 h",
            "Interleukin 8 Change From Baseline to 24 h",
            "RAGE Change From Baseline to 6 h",
            "RAGE Change From Baseline to 24 h"
      ],
      "OutcomeMeasureType": [
            "Primary",
            "Primary",
            "Primary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary"
      ],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [
            "Participants",
            "Participants",
            "Participants",
            "kPa",
            "units on a scale",
            "kPa",
            "units on a scale",
            "Participants",
            "Participants",
            "days",
            "days",
            "pg/mL",
            "pg/mL",
            "pg/mL",
            "pg/mL",
            "pg/mL",
            "pg/mL",
            "pg/mL",
            "pg/mL"
      ],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeMeasurementLowerLimit": [
            "-1.2",
            "-2.7",
            "-1.00",
            "-0.67",
            "-67.9",
            "-47.8",
            "-4",
            "-4",
            "0",
            "0",
            "4",
            "4",
            "-4706",
            "-1005",
            "-6404",
            "-4294",
            "-124",
            "-71",
            "-137",
            "-165",
            "-24",
            "-8",
            "-34",
            "-17",
            "-888",
            "-624",
            "-1118",
            "-1057"
      ],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [
            "10.8",
            "8.3",
            "-0.25",
            "-0.08",
            "14.9",
            "10.9",
            "0",
            "1",
            "23",
            "24",
            "24",
            "15",
            "-66",
            "2374",
            "47",
            "1029",
            "4",
            "17",
            "4",
            "39",
            "3",
            "1",
            "4",
            "-1",
            "-45",
            "-93",
            "-78",
            "-110"
      ],
      "OutcomeMeasurementValue": [
            "0",
            "0",
            "1",
            "0",
            "20",
            "5",
            "3.7",
            "3.5",
            "-0.50",
            "-0.33",
            "-30.3",
            "-19.5",
            "-2",
            "-1",
            "12",
            "3",
            "15",
            "5",
            "2",
            "17",
            "12",
            "8",
            "-1120",
            "287",
            "-2080",
            "-537",
            "-51",
            "-20",
            "-34",
            "-43",
            "-2",
            "-1",
            "-5",
            "-5",
            "-326",
            "-322",
            "-393",
            "-411"
      ],
      "OverallOfficialAffiliation": [
            "University of California, San Francisco"
      ],
      "OverallOfficialName": [
            "Michael A Matthay, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [
            "michael.matthay@ucsf.edu"
      ],
      "PointOfContactOrganization": [
            "University of California San Francisco"
      ],
      "PointOfContactPhone": [
            "415-502-7434"
      ],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [
            "Michael A. Matthay, MD"
      ],
      "PrimaryCompletionDate": [
            "March 9, 2017"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Within 6 h of study product infusion:\n\nIncrease in vasopressor dose to the following values or higher:\nNorepinephrine 10 \u03bcg/min\nPhenylephrine 100 \u03bcg/min\nDopamine 10 \u03bcg/kg per min\nEpinephrine 0.1 \u03bcg/kg per min or addition of a third vasopressor\nNew ventricular tachycardia, ventricular fibrillation or asystole\nNew cardiac arrhythmia requiring cardioversion\nHypoxaemia requiring an increase in FiO2 of 0\u00b72 or more and an increase in PEEP of 5\u00b70 or more to maintain SpO2 in the target range of 88-95%\nClinical scenario consistent with transfusion incompatibility or transfusion-related infection (eg, urticaria, new bronchospasm)",
            "Within 24 h of study product infusion\n\n\u2022 Any cardiac arrest or death",
            "Safety endpoint: Any unexpected severe adverse events in two groups"
      ],
      "PrimaryOutcomeMeasure": [
            "Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion",
            "Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion",
            "Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "6 hours",
            "24 hours",
            "12 months"
      ],
      "ReferenceCitation": [
            "Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gotts JE, Wiener-Kronish JP, Bajwa EK, Donahoe MP, McVerry BJ, Ortiz LA, Exline M, Christman JW, Abbott J, Delucchi KL, Caballero L, McMillan M, McKenna DH, Liu KD. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019 Feb;7(2):154-162. doi: 10.1016/S2213-2600(18)30418-1. Epub 2018 Nov 16.",
            "Wick KD, Leligdowicz A, Zhuo H, Ware LB, Matthay MA. Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS. JCI Insight. 2021 Jun 22;6(12). pii: 148983. doi: 10.1172/jci.insight.148983.",
            "Liu KD, Wilson JG, Zhuo H, Caballero L, McMillan ML, Fang X, Cosgrove K, Calfee CS, Lee JW, Kangelaris KN, Gotts JE, Rogers AJ, Levitt JE, Wiener-Kronish JP, Delucchi KL, Leavitt AD, McKenna DH, Thompson BT, Matthay MA. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care. 2014 Jul 3;4:22. doi: 10.1186/s13613-014-0022-z. eCollection 2014.",
            "Asmussen S, Ito H, Traber DL, Lee JW, Cox RA, Hawkins HK, McAuley DF, McKenna DH, Traber LD, Zhuo H, Wilson J, Herndon DN, Prough DS, Liu KD, Matthay MA, Enkhbaatar P. Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax. 2014 Sep;69(9):819-25. doi: 10.1136/thoraxjnl-2013-204980. Epub 2014 Jun 2."
      ],
      "ReferencePMID": [
            "30455077",
            "33974564",
            "25593740",
            "24891325"
      ],
      "ReferenceType": [
            "result",
            "derived",
            "derived",
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "University of California, San Francisco"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Michael A. Matthay"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Principal Investigator"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor-Investigator"
      ],
      "ResultsFirstPostDate": [
            "April 10, 2019"
      ],
      "ResultsFirstPostDateType": [
            "Actual"
      ],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [
            "January 15, 2019"
      ],
      "ResultsFirstSubmitQCDate": [
            "March 18, 2019"
      ],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "1U01HL108713-01"
      ],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [
            "https://reporter.nih.gov/quickSearch/1U01HL108713-01"
      ],
      "SecondaryIdType": [
            "U.S. NIH Grant/Contract"
      ],
      "SecondaryOutcomeDescription": [
            "Efficacy endpoint: PaO2:FiO2 change from baseline to day 3",
            "Murray score for acute lung injury. The range is 0 to 4. The higher score, the worst outcome.",
            "Oxygenation index with the following validated measure of respiratory function: FiO2 (%) x mean airway pressure / PaO2",
            "Sequential organ failure assessment score (SOFA). The SOFA score ranges from 0 to 24. The higher, the worse.",
            "Efficacy endpoint: all-cause mortality at day 28",
            "Efficacy endpoint: all-cause mortality at day 60",
            "Efficacy endpoint: Number of ventilator-free days to day 28.",
            "Efficacy endpoint: Non-pulmonary organ-failure-free days to day 28",
            "Biological markers of endothelial injury: angiopoietin 2",
            "Biological markers of endothelial injury: angiopoietin 2",
            "Biological markers of inflammation: interleukin 6",
            "Biological markers of inflammation: interleukin 6",
            "Biological markers of inflammation: interleukin 8",
            "Biological markers of inflammation: interleukin 8",
            "Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)",
            "Biological markers of alveolar epithelial injury: receptor for advanced glycation end products (RAGE)"
      ],
      "SecondaryOutcomeMeasure": [
            "PaO2:FiO2 Change From Baseline to Day 3",
            "Lung Injury Score From Baseline to Day 3",
            "Oxygenation Index Change From Baseline to Day 2",
            "SOFA Score Change From Baseline to Day 3",
            "Number of Patients Death to Day 28",
            "Mortality to Day 60",
            "Number of Ventilator-free Days to Day 28",
            "Non-pulmonary Organ-failure-free Days to Day 28",
            "Angiopoietin 2 Change From Baseline to 6 h",
            "Angiopoietin 2 Change From Baseline to 24 h",
            "Interleukin 6 Change From Baseline to 6 h",
            "Interleukin 6 Change From Baseline to 24 h",
            "Interleukin 8 Change From Baseline to 6 h",
            "Interleukin 8 Change From Baseline to 24 h",
            "RAGE Change From Baseline to 6 h",
            "RAGE Change From Baseline to 24 h"
      ],
      "SecondaryOutcomeTimeFrame": [
            "baseline and day 3",
            "baseline and day 3",
            "baseline and day 2",
            "baseline and day 3",
            "28 days",
            "60 days",
            "28 days",
            "28 days",
            "baseline and 6 hours",
            "baseline and 24 hours",
            "baseline and 6 hours",
            "baseline and 24 hours",
            "baseline and 6 hours",
            "baseline and 24 hours",
            "baseline and 6 hours",
            "baseline and 24 hours"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment",
            "Non-systematic Assessment"
      ],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [
            "Nervous system disorders",
            "Surgical and medical procedures",
            "Renal and urinary disorders",
            "Renal and urinary disorders",
            "Blood and lymphatic system disorders",
            "Blood and lymphatic system disorders",
            "Cardiac disorders",
            "Cardiac disorders",
            "Cardiac disorders",
            "Cardiac disorders",
            "Cardiac disorders",
            "Cardiac disorders",
            "Cardiac disorders",
            "Hepatobiliary disorders",
            "Hepatobiliary disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Blood and lymphatic system disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "General disorders"
      ],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "SeriousEventStatsNumAffected": [
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "1",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "3",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "2",
            "8",
            "2"
      ],
      "SeriousEventStatsNumAtRisk": [
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20",
            "40",
            "20"
      ],
      "SeriousEventStatsNumEvents": [
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "1",
            "0",
            "1",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "3",
            "0",
            "0",
            "1",
            "1",
            "0",
            "1",
            "0",
            "1",
            "2",
            "8",
            "2"
      ],
      "SeriousEventTerm": [
            "Lower extremity weakness",
            "Hospital readmission due to post-surgical pain",
            "Acute renal failure",
            "Hospital readmission due to pyelonephritis",
            "Acute leukemia",
            "Diffuse alveolar hemorrhage",
            "Death due to cardiac arrest",
            "Myocardial ischemia",
            "Bradycardia",
            "Tachycardia",
            "Pericardial effusion",
            "Heart block",
            "Ischemic stroke",
            "Liver abscess",
            "Acute pancreatitis",
            "Death due to worsening respiratory failure",
            "Worsening respiratory failure, recovered",
            "Aspiration pneumonitis",
            "Calvarial bone marrow abnormality",
            "Pulmonary embolism",
            "Death due to multi-organ failure"
      ],
      "StartDate": [
            "March 15, 2014"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "March 2019"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "March 27, 2014"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "March 19, 2014"
      ],
      "StudyFirstSubmitQCDate": [
            "March 24, 2014"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}